Poly(allylamine hydrochloride)-functionalized reduced graphene oxide for synergistic chemo-photothermal therapy.
To develop near-infrared (NIR) light-responsive reduced graphene oxide (RGO)-based nanocomposites with improved stability, biocompatibility and enhanced in vitro chemo-photothermal therapeutic efficiency. Poly(allylamine hydrochloride)-functionalized RGO-based nanocomposites (RGO-PAH) were synthesized and thoroughly characterized. In vitro biocompatibility, cellular uptake and in vitro synergistic chemo-photothermal therapeutic efficiency of drug-loaded RGO-PAH nanocomposites were evaluated along with elucidation of cell death mechanism. RGO-PAH nanocomposites showed excellent photothermal transduction, pH-dependent drug release, rapid internalization, high biocompatibility and highly efficient synergistic in vitro chemo-photothermal therapy via apoptosis induction through increase in intracellular reactive oxygen species (ROS) production followed by oxidative DNA damage. Excellent biocompatibility and highly efficient chemo-photothermal killing of cancer cells at a very low concentration reflects the potential of RGO-PAH as a NIR-responsive therapeutic agent for cancer therapy.